Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

Clinical course and outcomes of methamphetamine-dependent adults with psychosis.

Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R; Methamphetamine Treatment Project Corporate Authors.

J Subst Abuse Treat. 2008 Dec;35(4):445-50. doi: 10.1016/j.jsat.2007.12.004. Epub 2008 Feb 21.

PMID:
18294802
2.

Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period.

Gonzales R, Ang A, Marinelli-Casey P, Glik DC, Iguchi MY, Rawson RA; Methamphetamine Treatment Project Corporate Authors.

J Subst Abuse Treat. 2009 Dec;37(4):353-61. doi: 10.1016/j.jsat.2009.04.001. Epub 2009 Jun 23.

PMID:
19553066
3.

Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.

Marinelli-Casey P, Gonzales R, Hillhouse M, Ang A, Zweben J, Cohen J, Hora PF, Rawson RA; Methamphetamine Treatment Project Corporate Authors.

J Subst Abuse Treat. 2008 Mar;34(2):242-8. Epub 2007 Jun 27.

PMID:
17596903
4.

Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users.

Lapworth K, Dawe S, Davis P, Kavanagh D, Young R, Saunders J.

Addict Behav. 2009 Apr;34(4):380-5. doi: 10.1016/j.addbeh.2008.11.014. Epub 2008 Nov 24.

PMID:
19097704
5.

Status of methamphetamine users 2-5 years after outpatient treatment.

Rawson RA, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, Ling W.

J Addict Dis. 2002;21(1):107-19.

PMID:
11831496
6.

Criminal justice itreatment admissions for methamphetamine use in California: a focus on Proposition 36.

Anglin MD, Urada D, Brecht ML, Hawken A, Rawson R, Longshore D.

J Psychoactive Drugs. 2007 Nov;Suppl 4:367-81.

PMID:
18284103
7.

A review of the clinical pharmacology of methamphetamine.

Cruickshank CC, Dyer KR.

Addiction. 2009 Jul;104(7):1085-99. doi: 10.1111/j.1360-0443.2009.02564.x. Epub 2009 Apr 29. Review.

PMID:
19426289
8.

Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology.

Sim T, Simon SL, Domier CP, Richardson K, Rawson RA, Ling W.

J Addict Dis. 2002;21(1):75-89.

PMID:
11831502
10.

Psychopathology in methamphetamine-dependent adults 3 years after treatment.

Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA; Methamphetamine Treatment Project Corporate Authors.

Drug Alcohol Rev. 2010 Jan;29(1):12-20. doi: 10.1111/j.1465-3362.2009.00081.x.

11.

Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis.

Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murray RM.

Psychol Med. 2003 Nov;33(8):1407-14.

PMID:
14672249
12.

Two-year outcomes of treatment for methamphetamine use.

Brecht ML, Greenwell L, von Mayrhauser C, Anglin MD.

J Psychoactive Drugs. 2006 Nov;Suppl 3:415-26.

PMID:
17357533
13.

Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning.

Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R; Methamphetamine Treatment Project Corporate Authors.

Am J Addict. 2010 Sep-Oct;19(5):385-90. doi: 10.1111/j.1521-0391.2010.00061.x.

14.

The prevalence of psychotic symptoms among methamphetamine users.

McKetin R, McLaren J, Lubman DI, Hides L.

Addiction. 2006 Oct;101(10):1473-8.

PMID:
16968349
15.

Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.

McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R.

Drug Alcohol Rev. 2008 May;27(3):277-85. doi: 10.1080/09595230801919486.

PMID:
18368609
16.

Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.

McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL.

JAMA Psychiatry. 2013 Mar;70(3):319-24. doi: 10.1001/jamapsychiatry.2013.283.

PMID:
23303471
17.

The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.

Hester R, Lee N, Pennay A, Nielsen S, Ferris J.

Exp Clin Psychopharmacol. 2010 Dec;18(6):489-97. doi: 10.1037/a0021791.

PMID:
21186923
18.

A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.

Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J; Methamphetamine Treatment Project Corporate Authors.

Addiction. 2004 Jun;99(6):708-17.

PMID:
15139869
19.

A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.

Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, Shand D.

Drug Alcohol Rev. 2008 May;27(3):326-33. doi: 10.1080/09595230801935672.

PMID:
18368615
20.

Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment.

Lecomte T, Mueser KT, MacEwan W, Thornton AE, Buchanan T, Bouchard V, Goldner E, Brink J, Lang D, Kang S, Barr AM, Honer WG.

J Nerv Ment Dis. 2013 Dec;201(12):1085-9. doi: 10.1097/NMD.0000000000000059.

PMID:
24284645

Supplemental Content

Support Center